Will BioLife Solutions, Inc. (BLFS) Short Squeeze Soon? The Stock Formed a Double Top

August 10, 2018 - By Richard Slagle

BioLife Solutions, Inc. (NASDAQ:BLFS) Logo

Investors sentiment decreased to 0.79 in Q1 2018. Its down 2.04, from 2.83 in 2017Q4. It turned negative, as 5 investors sold BioLife Solutions, Inc. shares while 9 reduced holdings. 4 funds opened positions while 7 raised stakes. 1.33 million shares or 3.10% less from 1.37 million shares in 2017Q4 were reported.
Moreover, Perkins Capital Inc has 0.13% invested in BioLife Solutions, Inc. (NASDAQ:BLFS). Moreover, State Bank Of America Corporation De has 0% invested in BioLife Solutions, Inc. (NASDAQ:BLFS). Geode Cap Ltd invested in 0% or 69,384 shares. Granite Invest Ltd Company holds 111,402 shares or 0.04% of its portfolio. Blackrock Inc has invested 0% in BioLife Solutions, Inc. (NASDAQ:BLFS). Kopp Inv Lc invested 0.15% in BioLife Solutions, Inc. (NASDAQ:BLFS). Royal National Bank Of Canada reported 512 shares. Price T Rowe Associate Md has 0% invested in BioLife Solutions, Inc. (NASDAQ:BLFS) for 28,200 shares. Northern Tru holds 13,104 shares or 0% of its portfolio. Morgan Stanley reported 33 shares. Moreover, Citadel Lc has 0% invested in BioLife Solutions, Inc. (NASDAQ:BLFS). First Manhattan holds 0% or 12,000 shares in its portfolio. Deutsche Bancorp Ag has invested 0% in BioLife Solutions, Inc. (NASDAQ:BLFS). Pnc Svcs Grp Inc stated it has 0% of its portfolio in BioLife Solutions, Inc. (NASDAQ:BLFS). Janney Montgomery Scott Ltd Liability Corp holds 0% or 28,300 shares in its portfolio.

Since February 15, 2018, it had 0 insider purchases, and 15 selling transactions for $12.64 million activity. 12,540 BioLife Solutions, Inc. (NASDAQ:BLFS) shares with value of $65,960 were sold by Rice Michael. 10,000 BioLife Solutions, Inc. (NASDAQ:BLFS) shares with value of $112,500 were sold by Hinson Andrew G. Another trade for 214,286 shares valued at $2.44 million was sold by VILLIGER WALTER. 1.03 million shares were sold by GIRSCHWEILER THOMAS, worth $5.39 million. $69,059 worth of BioLife Solutions, Inc. (NASDAQ:BLFS) was sold by Schick Joseph C on Friday, June 1. COHEN RAYMOND W had sold 10,000 shares worth $101,500 on Wednesday, May 30.

The chart of BioLife Solutions, Inc. (BLFS) shows a double top with $22.00 target or 8.00 % above today’s $20.37 share price. The 8 months chart pattern indicates low risk for the $307.68M company. It was reported on Aug, 10 by Finviz.com. If the $22.00 price target is reached, the company will be worth $24.61M more. Double tops are rare but powerful chart patterns.

The stock increased 2.57% or $0.51 during the last trading session, reaching $20.37. About 149,108 shares traded. BioLife Solutions, Inc. (NASDAQ:BLFS) has risen 313.48% since August 10, 2017 and is uptrending. It has outperformed by 300.91% the S&P500.

BioLife Solutions, Inc. (NASDAQ:BLFS) Ratings Coverage

Among 3 analysts covering BioLife Solutions (NASDAQ:BLFS), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioLife Solutions had 3 analyst reports since March 12, 2018 according to SRatingsIntel. The firm has “Buy” rating by FBR Capital given on Thursday, June 7. The firm has “Buy” rating by Northland Capital given on Monday, March 12. Maxim Group maintained the shares of BLFS in report on Friday, May 11 with “Buy” rating.

More notable recent BioLife Solutions, Inc. (NASDAQ:BLFS) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Bellicum CFO Resigns, Roche’s Trial Meets Endpoints, Avid Bioservices Turns To …” on July 17, 2018, also Benzinga.com with their article: “50 Biggest Movers From Yesterday” published on July 31, 2018, Seekingalpha.com published: “BioLife Is Going Parabolic” on July 18, 2018. More interesting news about BioLife Solutions, Inc. (NASDAQ:BLFS) were released by: Investorplace.com and their article: “Improve Your Portfolio With These 5 Top Profitable Stocks” published on July 16, 2018 as well as Benzinga.com‘s news article titled: “The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo’s Positive Trial Results, Insys Earnings” with publication date: August 09, 2018.

BioLife Solutions, Inc. develops, manufactures, and markets patented hypothermic storage and cryopreservation solutions for cells and tissues in the United States. The company has market cap of $307.68 million. The Company’s products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, delayed-onset cell damage, and death. It currently has negative earnings. The firm offers HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications; and CryoStor cryopreservation freeze media products, which are designed to mitigate temperature-induced molecular cell stress responses during freezing and thawing.

BioLife Solutions, Inc. (NASDAQ:BLFS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.